AstraZeneca India Reports 48% Increase in Quarterly Profit

AstraZeneca India Reports 48% Increase in Quarterly Profit

Shares soar 12% after strong Q4 financial performance

AstraZeneca Pharma India Ltd has announced a notable *48% growth in consolidated net profit* for the fourth quarter of fiscal year 2025. The company’s profit stood at ₹58.25 crore, compared to ₹39.4 crore in the same quarter last year. Following this positive development, AstraZeneca’s shares climbed roughly *12%*, reflecting strong investor confidence.

Quarterly Revenue and Profit Details

In the last quarter, AstraZeneca recorded revenue of ₹480.48 crore from its operations, marking a *25.3% rise* compared to ₹383.19 crore reported in the previous year’s corresponding quarter. The profit before tax (PBT) rose to ₹67.59 crore, showing a significant jump from earlier quarters. Meanwhile, the operating profit (PBDIT) was ₹76.99 crore, with an operating margin of 17.49%, underscoring better cost management and efficiency.

Expanding Product Line and Strategy

Throughout FY25, the company broadened its product range by obtaining approvals for nine new medicines and indications. This expansion aligns with AstraZeneca’s strategy to target specialized therapeutic fields such as cancer, cardiovascular and kidney diseases, metabolic conditions, respiratory ailments, and rare disorders—areas that promise robust growth potential.

Dividend Declaration

In light of its solid financial performance, the board has proposed a final dividend of ₹24 per share for FY23-24, subject to approval by shareholders at the upcoming meeting.

Looking Ahead

With steady financial progress and a strong pipeline of specialized products, AstraZeneca Pharma India is well-positioned to capitalize on growing demand in the Indian pharmaceutical market. Experts anticipate the company will continue to see revenue and profit growth fueled by its focused therapeutic areas.

Summary:

AstraZeneca Pharma India reported a 48% year-over-year rise in net profit in Q4 FY25, driven by increased revenue and new drug approvals. Following the earnings announcement, shares surged 12%, while a final dividend of ₹24 per share was proposed.

The image added is for representation purposes only